Atrial Fibrillation, Postoperative Complications
Conditions
Keywords
landiolol
Brief summary
Postoperative atrial fibrillation (POAF) is the most common arrhythmia after cardiac surgery with incidences ranging from 20% to 40% with the consequence of increasing mortality, morbidity, and hospital length of stay, as well as increasing the costs to the health care system. To prevent POAF the use of beta-blockers is suggested by the EACTA and ESC guidelines. Despite the prophylactic use, the discontinuation of beta-blockers in the perioperative period is a known risk factor that contributes to the occurrence of POAF. Due to the short half time and the highly beta-1-selective properties of Landiolol, it could be possible to initiate a betablocker for prevention in the immediate postoperative setting, without adverse effects like hypotension or severe bradycardia as seen with other betablockers like Metoprolol or even sometimes Esmolol. Landiolol is already approved for the treatment of atrial tachycardias but is not yet approved for the use of prevention of POAF. In multiple previous studies the preventive potential of Landiolol in cardiac surgery could be proven in japanese study populations, with limitations due to limited sample sizes. In these trials the use of low-dose Landiolol effectively reduced the incidence of POAF without significant differences of increased side effects or in the hemodynamic stability compared to the placebo or standard of care groups. The primary objective of this prospective, double-blind, randomized, placebo-controlled phase III trial is to prove that the postoperative application of low-dose Landiolol significantly reduces the incidence of POAF without increased adverse events or hemodynamic instability compared to the placebo group after cardiac surgery in a non-Asian population.
Interventions
DRUGLandiolol HCl
continous 2mcg/kg/min low dose application of Landiolol HCl for 72 hours
DRUGPlacebo
continous application of isotone saline solution for 72 hours
Sponsors
Medical University of Vienna
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Male or female patients ≥ 18 years old 2. Written informed consent from patient 3. Patients are in sinus rhythm 4. Oral Betablocker in the patients long-term medication 5. One of the following cardiac surgical procedures which is planned on cardiopulmonary bypass (CPB): 1. Single valve surgery 2. Single or multiple CABG procedures 3. Single valve surgery in combination with one or multiple coronary artery bypass grafts (CABGs) 4. Multiple valve surgery in combination with or without CABG 5. Single or multiple valve surgery in combination with ascending aorta procedure with or without additional CABG 6. Re-surgery of aortic valve, mitral valve, aortic arch or ascending aorta with or without CABG 6. Cardiac surgery is performed electively
Exclusion criteria
1. Bodyweight \> 101kg and/or BMI ≥ 40 2. Cardiac surgery is planned as minimally invasive procedure (e.g., without thoracotomy or with lateral incision, minimal thoracotomy) or planned as off-pump surgery 3. Planned maze procedure, radiofrequency ablation, pulmonary vein ablation, resection of the atrial appendix or atrial resections during the surgery 4. Sinus bradycardia (resting heart rate \< 50/min) at screening and before start of IMP treatment 5. Second- or third-degree atrioventricular block at screening and before start of IMP treatment 6. Clinical hypothyroidism or hyperthyroidism at screening 7. History of ventricular arrhythmia 8. Permanent atrial fibrillation or atrial fibrillation at time of screening and IMP administration 9. Emergency cardiac surgery 10. Requiring inotropic, vasopressor or requiring ventilatory support at time of screening 11. Circulatory shock requiring mechanical circulatory support before initiation of study medication 12. Distributive shock (cardiac index\>2.2 L/min with norepinephrine dose \> 0.3 µg/kg/min to reach mean arterial pressure \> 65mmHg) before initiation of study medication 13. More than 5 units of RBC necessary to maintain a haemoglobin level \>8mg/dl at the end of surgery 14. Prior cardiac surgery within the past 6 months 15. History of heart transplantation or planned heart transplantation 16. Any other disease or condition that is likely to interfere with the evaluation of the study drug, outcome assessment or satisfactory conduct of the study: 1. Active infective endocarditis 2. Stroke or transient ischemic attack (TIA) within the last 6 months 3. Concomitant disease with a life expectancy of less than 6 months 4. Cardiopulmonary resuscitation within the last 4 weeks 5. Patients requiring renal replacement therapy 17. Active infection on current systemic antibiotics and/ or temperature greater than 38°C at time of screening and before start of surgery 18. Haemoglobin \< 5 mmol/l (\< 8.06 g/dl) 19. Any systemic anti-cancer therapy within past 3 months 20. Patients with known hypersensitivity to any constituent of the IMP 21. General
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary end point is a combined endpoint consisting of the occurrence of atrial fibrillation and mortality during the initial 72 hours period after surgery | 3 days | Death from any reason or the occurence of atrial in the holter ecg within 3 days after operation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hemodynamic stability during treatment with IMP | 7 days | Hemodynamic stability assessed with the need for vasoactive medication in the two groups within 7 days after operation |
| Length of ICU stay | 30 days | Postoperative length of stay in days in the icu |
| Requirement of intensive respiratory and circulatory support | 30 days | Length of invasive ventilation in hours or need for circulatory support |
| Peri- and postoperative mortality | 30 days | Peri- and postoperative mortality |
| Incidence/ frequency of occurrence of atrial fibrillation during the first seven days after cardiac surgery | 7 days | The occurence of AF in the holter ecg in the 7 days after the operation |
| Biomarker Assessment for cardiac injury, remodelling and fibrosis | 7 days | Biomarker assessment (TropT, CK, CK-MB, sST-2) for cardiac remodelling, fibrosis, apoptosis and ischemia reperfusion injury at time of start of the surgery, at ICU admission, 24 hours after ICU admission, 3 days and 7 days after surgery. |
| Incidence of serious adverse events | 30 days | Incidence of serious adverse events |
| Echocardiographic assessment for left ventricular function | 7 days | Echocardiographic assessment for left ventricular systolic, diastolic and valvular function 7 days after surgery |
| Assessment of biomarkers as surrogate parameters for cardiac dysfunction | 30 days | Assessment of cardiac biomarkers to evaluate cardiac dysfunction |
Countries
Austria
Contacts
Primary ContactAndreas Binder
Backup ContactBarbara Steinlechner
Outcome results
None listed